BLU-808 — Competitive Intelligence Brief

BLU-808 (BLU-808) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: KIT inhibitor. Area: Oncology.

phase 2 KIT inhibitor KIT Oncology Small molecule

Target snapshot

BLU-808 (BLU-808) — Blueprint Medicines Corporation. BLU-808 is a potent and selective KIT inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BLU-808 TARGET	BLU-808	Blueprint Medicines Corporation	phase 2	KIT inhibitor	KIT
Rydapt	MIDOSTAURIN	Novartis	marketed	Kinase Inhibitor [EPC]	Mast/stem cell growth factor receptor Kit	2017-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
Inlyta	axitinib	Pfizer	marketed	Kinase Inhibitor [EPC]	Mast/stem cell growth factor receptor Kit	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
PAZOPANIB HYDROCHLORIDE	PAZOPANIB HYDROCHLORIDE		marketed		VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (KIT inhibitor class)

1. Blueprint Medicines Corporation · 1 drug in this class